considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Published 6 months ago • 68 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
4:00
optimizing the outcomes of autohsct in multiple myeloma
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
5:06
bispecific antibodies: late side effects
-
6:09
bispecific antibodies | high impact topic (hit)
-
2:38
how close is a cure for multiple myeloma?
-
1:40
utilizing ai for individualized treatment-adjusted risk stratification in newly diagnosed myeloma
-
9:34
targeting of myeloma disease progression and bispecific antibody advantages
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:42
enhancing outcomes in multiple myeloma with immune-based strategies
-
3:02
optimal treatment strategies for multiple myeloma
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
4:22
optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
4:10
treatment-free intervals for patients with myeloma